Type of Application: U.S. Army Corps of Engineers (USACE) permit application #SWG-1997-02845. This application will be reviewed pursuant to Section 10 of the Rivers and Harbors Act of 1899 and Section 404 of the Clean Water Act (CWA). Note: The consistency review for this project may be conducted by the Texas Commission on Environmental Quality as part of its certification under Section 401 of the Clean Water Act.

CNP Project No: 19-1189-F1

Applicant: Dutko Family Partnership, LTD

Location: The project site is located in wetlands adjacent to Taylor Bayou and Galveston Bay, on a 107-acre tract, on the southeast corner of State Highway 146 and McCabe Road, in La Porte, Harris County, Texas.

Latitude & Longitude (NAD 83): 29.628270, -95.029684

Project Description: The applicant proposes to discharge fill material into 6.37 acres of palustrine forested wetlands during the construction of a commercial development.

Type of Application: U.S. Army Corps of Engineers (USACE) permit application #SWG-2018-00811. This application will be reviewed pursuant to Section 404 of the Clean Water Act (CWA). Note: The consistency review for this project may be conducted by the Texas Commission on Environmental Quality as part of its certification under Section 401 of the Clean Water Act.

CNP Project No: 19-1219-F1

Further information on the applications listed above, including a copy of the consistency certifications or consistency determinations for inspection, may be obtained from Ms. Allison Buchtien, P.O. Box 12873, Austin, Texas 78711-2873, or via email at federal.consistency@tceq.texas.gov. Comments should be sent to Ms. Buchtien at the above address or by email.

TRD-201900757
Mark A. Havens
Chief Clerk and Deputy Land Commissioner
General Land Office
Filed: March 6, 2019

Texas Health and Human Services Commission

Public Notice: Waiver Amendment of the Medically Dependent Children Program

The Texas Health and Human Services Commission (HHSC) is submitting to the Centers for Medicare & Medicaid Services (CMS) a request to amend the Medically Dependent Children Program (MDCP) waiver, which is implemented under the authority of section 1915(c) of the Social Security Act. CMS has approved this waiver through August 31, 2022. The proposed effective date for this amendment is August 31, 2019, with updates to the cost neutrality.

This amendment request proposes to make the following changes:

--Appendix J: The Cost Neutrality Demonstration information in appendix J will be updated for waiver years two through five as it relates to the projections for the comparison population reflected in G and G'.

--Appendix H.2 will be added to specify whether the state has deployed a patient experience of care or quality of life survey, including the type of survey tool utilized, for its Home and Community Based Services (HCBS) population in the last 12 months based on CMS direction.

--Appendix E will clarify in E-2 a. ii, the state's method to conduct background checks does not vary from Appendix C-2-a based on CMS direction.

The MDCP waiver provides home and community-based services to persons under age 21 who are medically fragile and meet the requirements for nursing facility care. Services include respite, adaptive aids, minor home modifications, employment assistance, supported employment, financial management services, transition assistance services, and flexible family support services. Texas uses the MDCP waiver to provide services to Texans in the least restrictive environment possible. These environments include the individual's or a family member's home, or a Child Protective Services foster care home which can meet the individual's complex medical needs.

An individual may obtain a free copy of the proposed waiver amendment, including the MDCP Home and Community Based Services (HCBS) transition plan, or ask questions, obtain additional information, or submit comments regarding this amendment or the MDCP HCBS transition plan by contacting Courtney Pool by U.S. mail, telephone, fax, or email. The addresses are as follows:

U.S. Mail
Texas Health and Human Services Commission
Attention: Courtney Pool, Waiver Coordinator, Policy Development Support
P.O. Box 13247
Mail Code H-600
Austin, Texas 78711-3247

Telephone
(512) 424-6889

Fax
Attention: Courtney Pool, Waiver Coordinator, at (512) 487-3403

Email
TX_Medicaid_Waivers@hhsc.state.tx.us

In addition, the HHSC local offices will post this notice for 30 days.

The complete waiver amendment request can be found online on the Health and Human Services website at:

TRD-201900730
Karen Ray
Chief Counsel
Texas Health and Human Services Commission
Filed: March 4, 2019

Department of State Health Services

Order Removing Hemp, as Defined by the Agricultural Marketing Act of 1946, From Schedule I

The United States Congress enacted the Agriculture Improvement Act of 2018 (Public Law No. 115-334) amending the definitions of marijuana and tetrahydrocannabinols in schedule I of the Controlled Substances Act, effective December 20, 2018. The amendments removed hemp, as defined in 297A of the Agricultural Marketing Act of 1946, from the schedules of controlled substances.
Pursuant to Section 481.034(g), as amended by the 75th legislature, of the Texas Controlled Substances Act, Health and Safety Code, Chapter 481, at least thirty-one days have expired since notice of the above referenced action was taken. In the capacity as Commissioner of the Texas Department of State Health Services, John Heterstedt, M.D., does hereby order that the listing for marihuaana and tetrahydrocannabinols be amended to align with the amendments in P.L. 115-334.

Schedule I hallucinogenic substances

Unless specifically excepted or unless listed in another schedule, a material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances or that contains any of the substance's salts, isomers, and salts of isomers if the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation (for the purposes of this Schedule I hallucinogenic substances section only, the term "isomer" includes optical, position, and geometric isomers):

1. Alpha-ethyltryptamine (some trade or other names: etryptamine, Monase, alpha-ethyl-H-indole-3-ethanamine; 3-(2-aminobutyl)indole; alpha-ET, AET);
2. alpha-methyltryptamine (AMT), its isomers, salts, and salts of isomers;
3. 4-bromo-2,5-dimethoxy-ethylamphetamine (some trade or other names: 4-bromo-2,5-dimethoxy-alpha-methylphenethylamine, 4-bromo-2,5-DMA);
4. 4-bromo-2,5-dimethoxyphenethylamine (some trade or other names: Nexus 2C-B, 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl-DOB);
5. 2,5-dimethoxyamphetamine (some trade or other names: 2,5-dimethoxy-alpha-methylphenethylamine, 2,5-DMA);
6. 2,5-dimethoxy-4-ethylamphetamine (some trade or other names: DOET);
7. 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its optical isomers, salts, and salts of isomers;
8. 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), its isomers, salts, and salts of isomers;
9. 5-methoxy-3,4-methylenedioxy-ethylamphetamine;
10. 4-methoxyamphetamine (some trade or other names: 4-methoxy-alpha-methylphenethylamine; paramethoxyamphetamine, PMA);
11. 1-methyl-4-phenyl-1,2,5,6-tetrahydro-pyridine (MPTP);
12. 4-methyl-2,5-dimethoxyamphetamine (some trade or other names: 4-methyl-2,5-dimethoxy-alpha-methylphenethylamine, "DOM", and "STP");
13. 3,4-methylenedioxy-amphetamine;
14. 3,4-methylenedioxy-methamphetamine (MDMA, MDM);
15. 3,4-methylenedioxy-N-ethylamphetamine (some trade or other names: N-ethyl-alpha-methyl-3,4-methylenedioxyphenethylamine, N-ethyl-MDA, MDEA);
16. 3,4,5-trimethoxy-amphetamine;
17. N-hydroxy-2,3,4-methylenedioxyamphetamine (Also known as N-hydroxy-MDA);
18. 5-methoxy-N,N-dimethyletryptamine (some trade or other names: 5-methoxy-3-[2-(dimethylamino)ethyl]indole, 5-MeO-DMT;
19. Bufoptene (some trade and other names: 3-(beta-Dimethylaminomethyl)-5-hydroxyindole; 3-(2 dimethylaminomethyl)-5-indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-dimethyletryptamine; maprine);
20. Diethyltryptamine (some trade and other names: N,N-diethyltryptamine; DET);
21. Dimethyltryptamine (some trade and other names: DMT);
22. Ethylamine Analog of Phencyclidine (some trade or other names: N-ethyl-1-phenylethylcyclohexylamine, 1-phenylethylcyclohexyl-ethylamine, N-ethylphenylethylcyclohexylamine, cyclohexamine, PCE);
23. Ibogaine (some trade or other names: 7-Ethyl-6,6-beta, 7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrado [1',2':1,2] azepino [5,4-b]-indole, tabernanthine iboga);
24. Lysergic acid diethylamide;
25. Marihuaana;

The term marihuaana does not include hemp, as defined in section 297A(1) of the Agricultural Marketing Act of 1946.

Mescaline;
N-ethyl-3-piperidyl benzilate;
N-methyl-3-piperidyl benzilate;
Parahexyl (some trade or other names: 3-ethyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo-[b,d]-pyran, Synhexyl);
Psycho, unless unharvested and growing in its natural state, meaning all parts of the plant classified botanically as Lophophora, whether growing or not, the seeds of the plant, an extract from a part of the plant, and every compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seeds, or extracts;
Psilocybin;
Psilocin;
Pyroolidine analog of phencyclidine (some trade or other names: 1-(1-phenyl-cyclohexyl)-pyroolidine, PCPy, PHP);
Tetrahydrocannabinols; meaning tetrahydrocannabinols naturally contained in a plant of the genus Cannabis (cannabis plant), except for tetrahydrocannabinols in hemp (as defined under section 297A(1) of the Agricultural Marketing Act of 1946), as well as synthetic equivalents of the substances contained in the cannabis plant, or in the resins extractives of such plant, and/or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity to those substances contained in the plant, such as the following:
1 cis or trans tetrahydrocannabinol, and their optical isomers;
6 cis or trans tetrahydrocannabinol, and their optical isomers;
3,4 cis or trans tetrahydrocannabinol, and its optical isomers;
(Since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions covered);
Thiophene analog of phencyclidine (some trade or other names: 1-[2 (thienyl)cyclohexyl] piperidine, 2 thienyl analog of phencyclidine, TCPy);
1-[(2 thienyl)cyclohexyl]-pyroolidine (some trade or other names: TCPy);
4-methylmescaline (Other names: 4-methyl-N-methylcathinone, mephedrone);
IN ADDITION  March 15, 2019  44 TexReg 1469

Texas Department of Housing and Community Affairs

Notice of Public Hearing: Multifamily Housing Revenue Bonds (Lago de Plata Apartments)

Notice is hereby given of a public hearing to be held by the Texas Department of Housing and Community Affairs (the "Issuer") at the City of Corsicana Public Library, 100 N. 12th Street, Corsicana, Texas 75110, at 6:00 p.m. on April 2, 2019. The hearing is regarding an issue of tax-exempt bonds in an aggregate principal amount not to exceed $14,000,000 and taxable bonds, if necessary, in an amount to be determined, to be issued in one or more series (the "Bonds"), by the Issuer. The Bonds will be issued as exempt facility bonds for a qualified residential rental project (the "Development") pursuant to section 142(a)(7) of the Internal Revenue Code of 1986, as amended (the "Code"). The Project is known as Lago de Plata Apartments and is located at 1600 East 13th Avenue, Corsicana, Navarro County, Texas 75110. The initial legal owner and principal user of the Development will be LHI Lago de Plata, LP, a Texas limited partnership, or a related person or affiliate thereof.

All interested parties are invited to attend such public hearing to express their views with respect to the Development and the issuance of the Bonds. Questions or requests for additional information may be directed to Shannon Roth at the Texas Department of Housing and Community Affairs, P.O. Box 13941, Austin, Texas 78711-3941, (512) 475-3929; and/or shannon.roth@tdhca.state.tx.us.

Persons who intend to appear at the hearing and express their views are invited to contact Shannon Roth in writing in advance of the hearing. Any interested persons unable to attend the hearing may submit their views in writing to Shannon Roth prior to the date scheduled for the hearing. Individuals who require a language interpreter for the public hearing should contact Elena Peinado at (512) 475-3814 at least five